News on protein analysis, clinical proteomics, biomarkers in genetics, genomics, and molecular diagnostics.
The company will use the funds to refine a nanoparticle-based immunoenrichment approach to simplifying sample separations up front of mass spec analysis.
The company also said that net income for the first half of 2017 rose 18 percent year over year to €101 million from €85.7 million.
The firm is looking for outside partners to tackle test commercialization as it begins to bring its second-generation colorectal cancer assay to market.
The platform received 510(k) clearance from the US Food and Drug Administration for the expanded identification of mycobacteria, Nocardia, and molds.
The new version of the mass spectrometry-based system adds 144 microbial species to its database and includes new tools for sample preparation.